The company has designed intensive commercial strategies for the distribution of our active molecular compounds all over the world.

Bionerics Research consequently has the spirit of a global company with international activity exclusively.

Bionerics Research will make use of the most complete pharmaceutical database, with scientific and commercial contents. Both, Bionerics own advanced technology joined to this mentioned database, will provide us with great knowledge of the most suitable business approach, as well as the most interesting disease target molecules to ensure peak competence in our core disease areas.

Bionerics Research compounds will be offered in 3 license lines all with pre-clinical ADME/toxic test already done:

• Silver license.- Compounds with in vitro positive activity/selectivity test to inhibit or modulate top interesting disease related protein targets. Although it is our basic license, Bionerics will follow, as in all our licences, top quality protocols for FDA or European pharmaceutical agencies protocol chain of requirements.
• Gold license.- Compounds with positive in vitro/in vivo tests with pathological cells. By positive it is meant: the reduction in the progress of a disease, the detention in the progress of a disease or the cure of said mentioned pathological cells.
• Platinum license.– Compounds with positive pre-clinical in vivo test. This license has all or almost all the pre-clinical test completed with positive results. By positive it is meant: the reduction in the progress of a disease, the detention in the progress of a disease or the cure of the pathology.

IMPORTANT: All three license lines above always with pre-clinical ADME/toxic test already done.